Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1239

Shown on this page

Current sort

Live official records

Conditions: COPD, Early-Onset
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 30 Years to 55 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: HIV, Opioid Use Disorder, eHealth
Interventions: Decision Aid, Athena strategy; Behavioral · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • New Haven, Connecticut

Conditions: Plaque Psoriasis
Interventions: TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 74
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more

Conditions: Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions: Avelumab, Cetuximab; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more

Conditions: Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions: DPA-714 PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cystic Fibrosis (CF)
Interventions: Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring; Drug · Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab, Dexamethasone, Carfilzomib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: MGL-3196, Placebo, Liver Biopsy; Drug · Procedure
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 90
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more

Conditions: End-Stage Kidney Disease, Hemodialysis Complication
Interventions: AV graft, surgical intervention for creation of a fistula; Device · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Interventions: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: George Solomon; Other
Eligibility: 17 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Live official records

SPIROMICS Study of Early COPD Progression (SOURCE)

Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

The Arteriovenous Vascular (AV) ACCESS Trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Rare CFTR Mutation Cell Collection Protocol (RARE)

About this University of Alabama at Birmingham institution page